HIV endemic has had devastating economic, social, health and psychological impacts over the years affecting millions of households in a significant manner over the last decade. Despite the concrete efforts from authorities and various philanthropic institutions, the numbers are still on an upward trend with a total of 33.3 Million HIV victims across the world till the end of 2009.
In such a scenario, the Highly Active Antiretroviral Therapy (HAART) has been very effective in reducing the number of HIV particles in the bloodstream, thus leading to a reduction in AIDS-related mortality. The market for this type of therapy has also expanded over time and reached to the mark of around US$ 12.6 Billion in 2010. Among all the key drugs in the market, multi-class combination product, Atripla dominates the HIV therapeutics market as products from other classes, such as NRTIs, NNRTIs, PIs, and Fusion Inhibitors are following the sales pattern. Our report has effectively analyzed the major marketed brands in the HIV therapeutics segment and presented a coherent research on the same.
A number of key HIV compounds are also in various phases of clinical trials being developed by companies like Gilead Sciences, Tibotec, etc. The HIV therapeutics market is attracting a huge amount of investment with majority of contribution coming from the public sector.
The report “Global HIV Therapeutics Market Analysis” analyzes the overall market size, and country level developments. It also provides the future landscape of global HIV therapeutics market which looks promising with the commercialization of new and innovative drugs. A brief description and recent activities of key market players have been included to show private sectors’ participation. Overall, the report is likely to provide intending clients with an effective insight into the global HIV therapeutics market.